Similar articles

• [Determination of tetanus toxin and toxoid by ELISA using monoclonal antibodies].

  Burkin MA, Sviridov VV, Perelygina OV. Burkin MA, et al. Prikl Biokhim Mikrobiol. 2004 Jul-Aug;40(4):478-84. Prikl Biokhim Mikrobiol. 2004. PMID: 15455723 Russian.
• [Split tetanus vaccine. Studies on its efficacy and tolerance as compared to adsorbed vaccine].

  Ambrosch F, Wiedermann G. Ambrosch F, et al. Fortschr Med. 1984 Aug 16;102(29-30):757-9. Fortschr Med. 1984. PMID: 6500445 Clinical Trial. German.
• Reduction of the ganglioside binding activity of the tetanus toxin HC fragment destroys immunogenicity: implications for development of novel tetanus vaccines.

  Qazi O, Sesardic D, Tierney R, Söderbäck Z, Crane D, Bolgiano B, Fairweather N. Qazi O, et al. Infect Immun. 2006 Aug;74(8):4884-91. doi: 10.1128/IAI.00500-06. Infect Immun. 2006. PMID: 16861677 Free PMC article.
• Current concepts in the management of Clostridium tetani infection.

  Brook I. Brook I. Expert Rev Anti Infect Ther. 2008 Jun;6(3):327-36. doi: 10.1586/14787210.6.3.327. Expert Rev Anti Infect Ther. 2008. PMID: 18588497 Review.
• Cellular immunology of tetanus toxoid.

  Corradin G, Watts C. Corradin G, et al. Curr Top Microbiol Immunol. 1995;195:77-87. doi: 10.1007/978-3-642-85173-5_4. Curr Top Microbiol Immunol. 1995. PMID: 8542760 Review. No abstract available.